Development of thioquinazolinones, allosteric Chk1 kinase inhibitors

Bioorganic and Medicinal Chemistry Letters

Volumn 19, Issue 4, 2009, Pages 1240-1244

  Converso, Antonella ^a   Hartingh, Timothy ^a   Garbaccio, Robert M ^a   Tasber, Edward ^a   Rickert, Keith ^a   Fraley, Mark E ^a   Yan, Youwei ^a   Kreatsoulas, Constantine ^a   Stirdivant, Steve ^a   Drakas, Bob ^a   Walsh, Eileen S ^a   Hamilton, Kelly ^a   Buser, Carolyn A ^a   Mao, Xianzhi ^a   Abrams, Marc T ^a   Beck, Stephen C ^a   Tao, Weikang ^a   Lobell, Rob ^a   Sepp Lorenzino, Laura ^a   Zugay Murphy, Joan ^a   Sardana, Vinod ^a   Munshi, Sanjeev K ^a   Jezequel Sur, Sylvie Marie ^a   Zuck, Paul D ^a   Hartman, George D ^a   more..

^a MERCK RESEARCH LABORATORIES   (United States)

Author keywords

Allosteric kinase inhibitor; Chk1; Thioquinazolinone; X ray crystal structure

Indexed keywords

ADENOSINE TRIPHOSPHATE; CHECKPOINT KINASE 1; CHECKPOINT KINASE 1 INHIBITOR; PROTEIN SERINE THREONINE KINASE INHIBITOR; QUINAZOLINONE DERIVATIVE; THIOQUINAZOLINONE DERIVATIVE; UNCLASSIFIED DRUG;

ALLOSTERISM; ARTICLE; CRYSTAL STRUCTURE; DRUG BINDING SITE; DRUG STABILITY; DRUG SYNTHESIS; ENZYME INHIBITOR INTERACTION; IC 50; REACTION ANALYSIS; STRUCTURE ACTIVITY RELATION;

BINDING SITES; COMBINATORIAL CHEMISTRY TECHNIQUES; CRYSTALLOGRAPHY, X-RAY; HUMANS; MOLECULAR CONFORMATION; MOLECULAR STRUCTURE; PROTEIN KINASE INHIBITORS; PROTEIN KINASES; QUINAZOLINES;

EID: 59649092904     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bmcl.2008.12.076     Document Type: Article

References (27)

1. Zhou B.B., and Bartek J. Nat. Rev. Cancer 4 (2004) 1
2. Bartek J., and Lukas J. Cancer Cell 3 (2003) 421
3. Kong N., Fotouhi N., Wovkulioch P.M., and Roberts J. Drugs Future 28 (2003) 881
4. Kawabe T. Mol. Cancer Ther. 3 (2004) 513
5. Prudhomme M. Recent Patents on Anti-Cancer Drug Discovery 1 (2006) 55
6. Cho S.H., Toouli C.D., Fujii G.H., Crain C., and Parry D. Cell cycle 4 (2005) 131
7. Luo Y., Rockow-Magnone S.K., Joseph M.K., Bradner J., Butler C.C., Tahir S.K., Han E.K.-H., Ng S.-C., Severin J.M., Gubbins E.J., Reilly R.M., Rueter A., Simmer R.L., Holzman T.F., and Giranda V.L. Anticancer Res. 21 (2001) 23
8. Koniaras K., Cuddihy A.R., Christopoulos H., Hogg A., and O'Connell M.J. Oncogene 20 (2001) 7453
9. Maude S.L., and Enders G.H. Cancer Res. 65 (2005) 780
10. Hattori H., Kuroda M., Ishida T., Shinmura K., Nagai S., Mukai K., and Imakiire A. Pathol. Int. 54 (2004) 26
11. Blagden S., and de Bono J. Current Drug Targets 6 (2005) 325
12. Chen Z., Xiao Z., Gu W.-Z., Xue J., Bui M.H., Kovar P., Li G.n., Wang G., Tao Z.-F., Tong Y., Lin N.-H., Sham H.L., Wang J.Y.J., Sowin T.J., Rosenberg S.H., and Zhang H. Int. J. Cancer 119 (2006) 2784
13. Manning G., Whyte D.B., Martinez R., Hunter T., and Sudarsanam S. Science 298 (2002) 1912
14. Weinmann H., and Metternich R. ChemBioChem 6 (2005) 1
15. Woodgett J. Protein Kinase Functions; Front. Mol. Biol. 29 (2000) 1
16. Fraley, M. E.; Steen, J. T. PCT Int. Appl. WO 2007015837, 2007.
17. Arrington, K. L.; Dudkin, V. Y.; Fraley, M. E.; Garbaccio, R. M.; Hartman, G. D.; Huang, Y.; Kreatsoulas, C.; Tasber, E. S., PCT Int. Appl. WO 2007008502, 2007.
18. Arrington, K. L.; Fraley, M. E.; Garbaccio, R. M.; Huang, S. Y.; Lindsley, C. W.; Steen, J. T.; Yang, F. PCT Int. Appl. WO 2006086255, 2006.
19. Brnardic, E. J.; Fraley, M. E.; Garbaccio, R. M.; Steen, J. T. PCT Int. Appl. WO 2006074281, 2006.
20. Fraley M.E., Steen J.T., Brnardic E.J., Arrington K.L., Spencer K.L., Hanney B.A., Kim Y., Hartman G.D., Stirdivant S.M., Drakas B.A., Rickert K., Walsh E.S., Hamilton K., Buser C.A., Hardwick J., Tao W., Beck S.C., Mao X., Lobell R.B., Sepp-Lorenzino L., Yan Y., Ikuta M., Munshi S.K., Kuo L.C., and Kreatsoulas C. Bioorg. Med. Chem. Lett. 23 (2006) 6049
21. Huang S., Garbaccio R.M., Fraley M.E., Steen J., Kreatsoulas C., Hartman G., Stirdivant S., Drakas B., Rickert K., Walsh E., Hamilton K., Buser C.A., Hardwick J., Mao X., Abrams M., Beck S., Tao W., Lobell R., Sepp-Lorenzino L., Yan Y., Ikuta M., Murphy J., Sardana V., Munshi S., Kuo L., Reilly M., and Mahan E. Bioorg. Med. Chem. Lett. 22 (2006) 5907
22. 3+ to XL665, and fluorescence emission from XL665 at 665 nm. In this assay, an inhibitor of Chk1 enzyme could be detected by a decrease of fluorescence.
23. Bhargava P.R., and Ram P. Bull Chem. Soc. Jpn. 38 (1967) 342
24. 3CN gradient w/0.1% TFA present) to yield pure product 5.
25. 50 values.
26. sym = 0.066 and completeness = 98%, respectively. The complex structures were refined to an R-factor of 0.182. The chlorobenzene ring of compound 38 has two conformations at 70% and 30% occupancies, respectively. The detailed X-ray diffraction data and refinement statistics are listed under PDB code 3F9N at the protein data bank. The crystallographic parameters are reported in the supporting information for this article.
27. Owen D.J., Noble M.E., Garman E.F., Papageorgiou A.C., and Johnson L.N. Structure 3 (1995) 467